of IP formation was shown to be specific for TRH-Rs using GH,C, cells expressing both TRH-Rs and receptors for bombesin. In these cells, CDE inhibited TRH-stimulated IP formation, but had no effect on bombesin-stimulated IP formation. The effects of chronic administration of CDE were studied. Preincubation of AtT-C33!Stop* cells, but not AtT-WT cells, with CDE for several hours caused an increase in cell surface receptor number (up-regulation) that is demonstrated when a drug binds to a receptor that exhibits constitutive activity and reduces this activity. Although first described in other receptor systems (4), negative antagonism has been shown to occur with guanine nucleotide-binding (G) protein-coupled receptors (GPCRs), for example opioid (5, 6), /3,-adrenergic (3, 7, 8) , serotonin type 2C (9), bradykinin (lo), and Dl B dopamine receptors (11).
Constitutive activity has been reported with native and mutant GPCRs (1, 12). We have described a mutant TRH receptor (TRH-R) that is a GPCR (13) and exhibits constitutive activity (C335Stop TRH-R) (14). Previously, AtT-C335Stop cells were reported to exhibit basal IP formation rates, that is TRH-independent IP formation rates, that were 32% higher, on the average, than those in AtT-WT cells (14). There was, however, variability in basal IP production, and in some clones, the rate in AtT-C335Stop cells was 2-to 3-fold higher than that in AtT-WT cells. In no AtT-WT clone was the basal rate of IP formation higher than in any clone. Clones of AtT-C335Stop cells in which basal IP production was 2.5-fold higher than that in AtT-WT cells were used for studies of the effect of CDE on basal IP formation. Figure 1 illustrates the effect of CDE on basal IP formation.
In AtT-WT cells, the basal rate of IP formation was low (2.19 2 0.35% of the total lipid plus IP radioactivity/h).
In contrast, the rate of IP formation in AtT-C335Stop cells was 5.57 t 0.44%/h in these experiments.
There was no significant effect of CDE on IP formation in mocktransfected cells or in AtT-WT cells. In contrast, CDE TRH-Rs exhibited constitutive activity in HeLa cells and CDE caused the basal IP formation rate in HeLa cells expressing C335Stop TRH-Rs to be decreased to the same level as that in HeLa cells expressing WT TRH-Rs (Fig. 2) .
It was possible that CDE nonspecifically lowered IP formation stimulated by any mechanism. To show that CDE specifically inhibited IP formation stimulated by activated TRH-Rs, the effect of CDE on IP formation stimulated by TRH was compared with that stimulated by bombesin in GH,C, cells expressing both GPCRs. A similar approach to show specificity was used by other investigators (18). Figure 3 shows that CDE inhibits TRH-stimulated IP formation, but does not inhibit bombesin-stimulated IP production. Thus, the effect of CDE is specific for IP formation stimulated by activated TRH-Rs.
It was shown that constitutively active &-adrenergic receptors may be chronically down-regulated in the absence of agonist and that negative antagonists could reverse this effect, that is up-regulate ,6,-adrenergic receptors (7). In contrast, negative antagonists have been shown to cause down-regulation of serotonin type 2C receptors (9). To study the regulation of Constitutively Active TRH Receptor and AtT-WT cells. Preincubation of AtT-WT cells with CDE had no effect on rH]MeTRH binding (maximal binding, 97 t 13% of the control; P > 0.1; the K, was not changed). In contrast, CDE caused the number of receptors in AtT-C335Stop cells to increase to 143 t 7% of the control value (P < 0.005, by paired t test; n = 4); preincubation with CDE had no effect on the binding affinity of C335Stop TRHRs. This increase in the number of receptors in MTC335Stop cells induced by CDE was measurable within 3 h of incubation (data not shown).
The functional consequences of CDE-induced upregulation of C335Stop TRH-Rs are illustrated in Figs. 5 and 6. There was no effect of CDE on subsequent TRH stimulation of IPs in AtT-WT cells; maximal stimulation by TRH was 114 + 13% of the control value (P > O.l), and the EC,, was not changed (Fig. 5) . This is consistent with the lack of effect of CDE preincubation on TRH-R number in AtT-WT cells. In contrast, CDE preincubation caused maximal TRH stimulation of IP formation to increase to 188 rt 45% of the control (P < 0.04; n = 5) in AtT-C335Stop cells. There was no effect of CDE on the EC when stimulation was initiated through another GPCR, namely that for bombesin. Thus, these findings extend the concept of negative antagonism of GPCRs (4) to the TRH-R that has a peptide as its cognate agonist and signals via the phosphoinositide cascade (19). WT TRH-Rs are down-regulated after being isomerized to the active state by TRH (20). Because negative antagonists appear to act by restraining receptors in an inactive conformation (3, lo), CDE was used to determine whether C335Stop TRH-Rs, for which a fraction of the receptors are in an active state in the absence of agonist (14), were down-regulated in AtT-20 cells. If C335Stop TRH-Rs were down-regulated, then CDE might reverse this effect and allow the number of C335Stop TRH-Rs to increase (up-regulate) in a fashion similar to that reported for constitutively active &-adrenergic receptors (7). CDE was shown to cause cell surface receptor up-regulation in AtTC335Stop cells, but not in AtT-WT cells. Thus, C335Stop TRH-Rs are chronically down-regulated in AtT-20 cells in the absence of ligands.
Up-regulation of C335Stop TRH-Rs by CDE was associated with increased TRH stimulation of IP formation and elevation of [Ca*'] ,. This observation is consistent with the previously reported tight correlation between the TRH-R level and the magnitude of the IP response to TRH in cells in which WT TRH-Rs were down-regulated (21). The EC,, values of TRH stimulation in TRH-R down-regulated cells were not affected. This is different from what has been found in other GPCR systems, in which activated receptors are both down-regulated and exhibit decreased sensitivity to agonist activation, that is higher agonist EC,, values (22). Indeed, negative antagonists up-regulated and increased the sensitivity of constitutively activated p2-adrenergic receptors (7). The absence of an effect to change TRH-R sensitivity may reflect differences from the 6,-adrenergic receptor system in the nature of the agonist-receptor-G protein-effector complex (23). TRH-R couples to G,, , to activate the effector phosphoinositide-specific phospholipase Cpl (PPI-PLCpl) (24, 25) . Because PPI-PLCpl is a GTPase-activating protein for GW,, and the rate of GTP hydrolysis was too rapid to allow a new receptor/G protein encounter before each GTP for GDP exchange, Berstein et al. (26) postulated that a relatively stable complex is Constitutively Active TRH Receptor 1459 formed comprised of agonist-receptor-G,,, , -PPIPLCpl The finding that Gq,,, is transferred from the plasma membrane to a light vesicular fraction with activated ml -muscarinic acetylcholine receptors supports this idea (27) . It has been suggested that a similarly stable complex comprised of TRH-TRH-R-G q,, ,-PPI-PLCpl also forms during TRH action (23). A corollary of this hypothesis is that, in contrast to receptors that couple to G, protein and adenylyl cyclase, in which there appears to be rapid dissociation of receptor from G, and reassociation of activated receptor with another G, (28), there is no amplification of the TRH signal at the level of receptor-G protein coupling. The absence of amplification at this step may underlie the lack of an effect on agonist sensitivity observed in the TRH-TRH-R system.
It is interesting that C335Stop TRH-Rs are downregulated in 
